GILD logo
GILD
Gilead Sciences

Lenacapavir And Trodelvy Launches Will Serve A Growing Aging Market

Published
08 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$140.00
18.0% undervalued intrinsic discount
06 Aug
US$114.77
Loading
1Y
49.1%
7D
-2.7%

Author's Valuation

US$140.0

18.0% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 0.13%

Read more

Shared on30 Apr 25
Fair value Decreased 0.014%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 0.14%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25

Read more